Who are NTX/BUP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zubsolv sublingual tablets, Suboxone (SCH 000484), Buprenorphine, Naloxone Drug Combination, Buprenorphine Naloxone, Oxycodone Naltrexone (a), Oxycodone Naltrexone (b).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ntx-bup.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

NTX/BUP — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NTX/BUP (NTX/BUP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist-antagonist combination. Area: Psychiatry / Addiction Medicine.

phase 3 Opioid agonist-antagonist combination Mu-opioid receptor (μ-OR) Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

NTX/BUP (NTX/BUP) — Alkermes, Inc.. NTX/BUP is a fixed-dose combination of naltrexone (an opioid antagonist) and buprenorphine (a partial opioid agonist) that reduces opioid cravings and withdrawal symptoms while blocking euphoric effects of additional opioid use.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NTX/BUP TARGET	NTX/BUP	Alkermes, Inc.	phase 3	Opioid agonist-antagonist combination	Mu-opioid receptor (μ-OR)
Zubsolv sublingual tablets	Zubsolv sublingual tablets	Indivior Inc.	marketed	Opioid agonist-antagonist combination	Mu-opioid receptor (buprenorphine); opioid receptors (naloxone antagonism)
Suboxone (SCH 000484)	Suboxone (SCH 000484)	Merck Sharp & Dohme LLC	marketed	Opioid agonist-antagonist combination	Mu-opioid receptor (buprenorphine); opioid receptors (naloxone)
Buprenorphine, Naloxone Drug Combination	Buprenorphine, Naloxone Drug Combination	The University of Texas Health Science Center, Houston	marketed	Opioid agonist-antagonist combination	Mu-opioid receptor (buprenorphine as partial agonist; naloxone as antagonist)
Buprenorphine Naloxone	Buprenorphine Naloxone	Johns Hopkins University	marketed	Opioid agonist-antagonist combination	Mu-opioid receptor (buprenorphine as partial agonist; naloxone as antagonist)
Oxycodone Naltrexone (a)	Oxycodone Naltrexone (a)	Elite Laboratories, Inc	phase 3	Opioid agonist-antagonist combination	Mu-opioid receptor (oxycodone agonist); opioid receptors (naltrexone antagonist)
Oxycodone Naltrexone (b)	Oxycodone Naltrexone (b)	Elite Laboratories, Inc	phase 3	Opioid agonist-antagonist combination	Mu-opioid receptor (oxycodone); opioid receptors (naltrexone antagonism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist-antagonist combination class)

New York State Psychiatric Institute · 2 drugs in this class
Elite Laboratories, Inc · 2 drugs in this class
Alkermes, Inc. · 2 drugs in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Orexo AB · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
Indivior Inc. · 1 drug in this class
Johns Hopkins University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NTX/BUP — Competitive Intelligence Brief. https://druglandscape.com/ci/ntx-bup. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing